In a phase II open-label study ledipasvir, sofosbuvir and ribavirin were used to treat HCV-infected patients who have advanced liver disease and who had or had not undergone liver transplantation. Patients (n = 337) with either HCV genotype 1 (99%) or genotype 4 (1%) were treated for either 12 or 24 weeks. Sustained virologic response (SVR) was assessed 12 weeks after treatment. SVR12 was reached in 86–89% of those who were not transplant recipients. SVR12 ranged from 60–96% in transplant recipients depending on the severity of liver disease. Owing to adverse events, 13 (4%) patients discontinued treatment.